Talks
TRIPLETE Study: PFS Results
March 4, 2026
TRIPLETE Study: Key Takeaways
March 4, 2026
TRIPLETE Study: Clinical Considerations
March 4, 2026
TRIPLETE Study: OS Results
March 4, 2026
TRIPLETE Study: Secondary Tumor Response Outcomes
March 4, 2026
TRIPLETE Study: ORR Results
March 4, 2026
TRIPLETE Study: Design & Endpoints
March 4, 2026
TRIPLETE Study: Patient Population
March 4, 2026
TRIPLETE Study: Understanding the Treatment Strategies
March 4, 2026
TRIPLETE Study: Overview
March 4, 2026
Neoantigen-Specific TIL in GI Cancers: The Future
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Safety
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Prognostic Factors
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Tumor Shrinkage
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Results
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Treatment Groups
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Patient Population
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: The New Idea
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: What is TIL Therapy?
February 28, 2026
Neoantigen-Specific TIL in GI Cancers: Trial Overview
February 28, 2026
The Future of IBS Care
January 24, 2026
Changing Practice in Gastric Cancer
January 27, 2026
Interstitial Lung Disease: A Key Risk
January 27, 2026
Adverse Events
January 27, 2026
Subgroup Analyses
January 27, 2026
Disease control and response duration
January 27, 2026
Primary Outcome: Overall Survival
January 27, 2026
Patient Characteristics
January 27, 2026
Trial Design
January 27, 2026
Introducing the contenders
January 27, 2026
DESTINY-Gastric04 Clinical Trial
January 27, 2026
Post-Infection IBS and Leaky Gut
January 24, 2026
Diet, Enzymes, and Bacterial Overgrowth
January 24, 2026
Bile Acid Malabsorption
January 24, 2026
Hypermobility, Mast Cells, and IBS
January 24, 2026
Autonomic Dysfunction and POTS
January 24, 2026
Neuromodulators: Matching Drug to Gut
January 24, 2026
Biomarkers: Psychological symptoms
January 24, 2026
IBS Clinical features and biomarkers-2
January 24, 2026
IBS Clinical features and biomarkers
January 24, 2026
Reducing Bias Through Real-Time Data
July 27, 2025
Capturing Symptom Interactions
July 27, 2025
Usability and Compliance
July 27, 2025
Advancing Precision Medicine in IBS
July 27, 2025
Reliability Despite Symptom Variability
July 27, 2025
Internal Consistency Across Symptom Doma
July 27, 2025
Weaker Correlations With End-of-Week Too
July 27, 2025
Retrospective Bias in End-of-Day Diaries
July 27, 2025
High Adherence Supports ESM Feasibility
July 19, 2025
Validating Real-Time Symptom Assessment
July 19, 2025
What’s Next?
July 7, 2025
Limitations and Learning
July 7, 2025
Observer Agreement
July 7, 2025
ME-OE: Better Accuracy, Sensitivity
July 7, 2025
Higher Yields with ME-OE
July 7, 2025
The Trial Design
July 7, 2025
Introducing ME-OE
July 7, 2025
White-Light Endoscopy: A Limitation?
July 7, 2025
The Correa Cascade
July 7, 2025
Why Gastric Cancer Detection Matters
July 7, 2025
Close button
Why are you reporting this TALK?